Istesso’s ground-breaking research hits the headlines
Recent press coverage of our work to develop healthspan-extending drugs recognises their potential to offer “a more sustainable path to healthier, longer lives”
4th December 2025
Istesso provides updates on leramistat and next-generation programs
Advancement of leramistat, a first-in-class mitochondrial complex I modulator (MCM),...
26th November 2025
Ground-breaking data demonstrates tissue repair with Istesso’s novel investigational medicines
Istesso’s new class of developmental drugs, which inhibit mitochondrial complex...
17th July 2025
Istesso appoints Dr Mike Owen to Board of Directors
Istesso, the leading adaptive tissue-repair company, is pleased to announce...
4th June 2025
Istesso announces FDA Fast Track and Orphan Drug designation for MBS2320
Istesso Limited, the programmed disease resolution company, today announces that...
5th December 2022
MBS2320 administered to participants with moderate-to-severe Rheumatoid Arthritis
Istesso Limited, the programmed disease resolution company, today announces the...
6th September 2022
Potential of Istesso’s MBS2320 hits the headlines
Istesso Limited (“Istesso’’) was featured on Thisismoney.co.uk over the weekend,...
30th August 2022
MBS2320 Phase 2a headline results announced
Istesso Limited (“Istesso’’) today announces headline results from the Phase...
15th July 2019
Istesso adds a further £4 million to fundraise
Istesso Limited (“Istesso’’) today announces that it has completed a...
1st February 2019